Aprea Therapeutics, Inc.(APRE), a clinical-stage biopharmaceutical company, Monday announced that it has dosed a patient with HPV+ Head and Neck Squamous Cell Carcinoma or HNSCC in its ongoing ACESOT-1051 clinical trial.
This is the first patient to be dosed in Cohort 5 of the study, which involves a 70 mg once-daily dose of APR-1051, a WEE1 inhibitor.
The study is evaluating APR-1051 in patients with advanced solid tumors, including HPV+ HNSCC.
The trial aims to explore the potential of WEE1 inhibition, which targets tumor cells with high replication stress and DNA damage accumulation.
HPV-driven cancers, including HPV+ HNSCC, are particularly susceptible to this treatment due to defects in their DNA damage repair pathways.
Aprea is focusing on identifying patient populations most likely to benefit from WEE1 inhibition.
The trial is progressing well, and the company is encouraged by the safety profile of APR-1051.
The ACESOT-1051 study will also explore the optimal dose for future studies, with preliminary open-label data expected in the second half of 2025.
Additionally, Aprea recently entered into a Material Transfer Agreement or MTA with MD Anderson Cancer Center to support preclinical research on the potential of APR-1051 for treating HPV+ and HPV- HNSCC.
The trial is being conducted at multiple sites, including MD Anderson Cancer Center.
Currently, APRE is trading at $2.06 down by 0.96 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com